Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

Similar articles for PubMed (Select 23337929)

1.

Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts.

Yip BH, Vuppusetty C, Attwood M, Giagounidis A, Germing U, Lamikanra AA, Roberts DJ, Maciejewski JP, Vandenberghe P, Mecucci C, Wainscoat JS, Pellagatti A, Boultwood J.

Leukemia. 2013 Aug;27(8):1760-3. doi: 10.1038/leu.2013.20. Epub 2013 Jan 22. No abstract available.

PMID:
23337929
2.

L-Leucine improves the anaemia in models of Diamond Blackfan anaemia and the 5q- syndrome in a TP53-independent way.

Narla A, Payne EM, Abayasekara N, Hurst SN, Raiser DM, Look AT, Berliner N, Ebert BL, Khanna-Gupta A.

Br J Haematol. 2014 Nov;167(4):524-8. doi: 10.1111/bjh.13069. Epub 2014 Aug 7.

PMID:
25098371
3.

FOXO3-mTOR metabolic cooperation in the regulation of erythroid cell maturation and homeostasis.

Zhang X, Campreciós G, Rimmelé P, Liang R, Yalcin S, Mungamuri SK, Barminko J, D'Escamard V, Baron MH, Brugnara C, Papatsenko D, Rivella S, Ghaffari S.

Am J Hematol. 2014 Oct;89(10):954-63. doi: 10.1002/ajh.23786. Epub 2014 Jul 22.

PMID:
24966026
4.

[Effect of mTOR signaling pathway in epileptogenesis].

Zeng L, Ding M.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2013 Nov;42(6):597-601. Chinese. No abstract available.

PMID:
24421222
5.

Genetics. Mysterious ribosomopathies.

McCann KL, Baserga SJ.

Science. 2013 Aug 23;341(6148):849-50. doi: 10.1126/science.1244156. No abstract available.

6.

Diminutive somatic deletions in the 5q region lead to a phenotype atypical of classical 5q- syndrome.

Vlachos A, Farrar JE, Atsidaftos E, Muir E, Narla A, Markello TC, Singh SA, Landowski M, Gazda HT, Blanc L, Liu JM, Ellis SR, Arceci RJ, Ebert BL, Bodine DM, Lipton JM.

Blood. 2013 Oct 3;122(14):2487-90. doi: 10.1182/blood-2013-06-509935. Epub 2013 Aug 13.

7.

Initial experience with L-leucine therapy in myelodysplastic syndromes with associated chromosome 5q deletion.

Steensma DP, Ebert BL.

Blood. 2013 May 23;121(21):4428. doi: 10.1182/blood-2013-03-493809. No abstract available.

8.
9.

Bidirectional regulation of nuclear factor-κB and mammalian target of rapamycin signaling functionally links Bnip3 gene repression and cell survival of ventricular myocytes.

Dhingra R, Gang H, Wang Y, Biala AK, Aviv Y, Margulets V, Tee A, Kirshenbaum LA.

Circ Heart Fail. 2013 Mar;6(2):335-43. doi: 10.1161/CIRCHEARTFAILURE.112.000061. Epub 2013 Feb 8.

10.

Distinct functions of erythropoietin and stem cell factor are linked to activation of mTOR kinase signaling pathway in human erythroid progenitors.

Geslain R, Uddin S, Liu H, Jiang H, van Besien K, Pan T, Wickrema A.

Cytokine. 2013 Jan;61(1):329-35. doi: 10.1016/j.cyto.2012.10.017. Epub 2012 Nov 11.

PMID:
23148990
11.

[5q--syndrome, MDS with isolated del(5q)].

Tohyama K.

Nihon Rinsho. 2012 Apr;70 Suppl 2:362-6. Japanese. No abstract available.

PMID:
23133983
12.

PARP-1 modulation of mTOR signaling in response to a DNA alkylating agent.

Ethier C, Tardif M, Arul L, Poirier GG.

PLoS One. 2012;7(10):e47978. doi: 10.1371/journal.pone.0047978. Epub 2012 Oct 24.

13.

Acquired EVI1 rearrangement involved in the transformation from 5q- syndrome to pre-B lymphocytic leukemia in a Chinese patient.

Liu D, Chen S, Pan J, Zhu M, Wu N, Zhu F, Chen Z.

Int J Hematol. 2012 Dec;96(6):806-9. doi: 10.1007/s12185-012-1185-8. Epub 2012 Oct 9.

PMID:
23054648
14.

Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q- syndrome and other ribosomopathies.

Boultwood J, Yip BH, Vuppusetty C, Pellagatti A, Wainscoat JS.

Adv Biol Regul. 2013 Jan;53(1):8-17. doi: 10.1016/j.jbior.2012.09.002. Epub 2012 Sep 13. Review.

PMID:
23031788
15.

PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection.

Chong ZZ, Shang YC, Wang S, Maiese K.

PLoS One. 2012;7(9):e45456. doi: 10.1371/journal.pone.0045456. Epub 2012 Sep 18.

16.

Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.

Oliva EN, Cuzzola M, Aloe Spiriti MA, Poloni A, Laganà C, Rigolino C, Morabito F, Galimberti S, Ghio R, Cortelezzi A, Palumbo GA, Sanpaolo G, Finelli C, Ricco A, Volpe A, Rodà F, Breccia M, Alimena G, Nobile F, Latagliata R.

Ann Hematol. 2013 Jan;92(1):25-32. doi: 10.1007/s00277-012-1569-0. Epub 2012 Sep 16.

PMID:
22983750
17.

Transcription factors Fli1 and EKLF in the differentiation of megakaryocytic and erythroid progenitor in 5q- syndrome and in Diamond-Blackfan anemia.

Neuwirtova R, Fuchs O, Holicka M, Vostry M, Kostecka A, Hajkova H, Jonasova A, Cermak J, Cmejla R, Pospisilova D, Belickova M, Siskova M, Hochova I, Vondrakova J, Sponerova D, Kadlckova E, Novakova L, Brezinova J, Michalova K.

Ann Hematol. 2013 Jan;92(1):11-8. doi: 10.1007/s00277-012-1568-1. Epub 2012 Sep 11.

PMID:
22965552
19.

L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway.

Payne EM, Virgilio M, Narla A, Sun H, Levine M, Paw BH, Berliner N, Look AT, Ebert BL, Khanna-Gupta A.

Blood. 2012 Sep 13;120(11):2214-24. doi: 10.1182/blood-2011-10-382986. Epub 2012 Jun 25.

20.

Leucine stimulates insulin secretion via down-regulation of surface expression of adrenergic α2A receptor through the mTOR (mammalian target of rapamycin) pathway: implication in new-onset diabetes in renal transplantation.

Yang J, Dolinger M, Ritaccio G, Mazurkiewicz J, Conti D, Zhu X, Huang Y.

J Biol Chem. 2012 Jul 13;287(29):24795-806. doi: 10.1074/jbc.M112.344259. Epub 2012 May 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk